인도의 의료 콜드체인 물류 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the india healthcare cold chain logistics market size is expected to grow from USD 8.72 billion in 2025 to USD 9.27 billion in 2026 and is forecast to reach USD 12.40 billion by 2031 at 5.99% CAGR over 2026-2031.

The market is shifting from bulk, ambient drug movement toward more controlled handling for vaccines, biologics, specialty injectables, and other temperature-sensitive therapies, which is raising the value of validated storage, monitored transport, and documented handoffs. This report is Segmented by Logistics Function (Transportation, and More), by Temperature Type (Chilled, Frozen, and More), by Product Type (Pharmaceuticals, Biopharmaceuticals, and More), by Destination (Domestic, International), by End User (Hospitals & Clinics, and More), and by Geography (North, Central, West, and More). The Market Forecasts are Provided in Terms of Value (USD).

India Healthcare Cold Chain Logistics Market Trends and Insights

Vaccine and Immunization Throughput Expansion

India's Universal Immunization Program covers 2.9 crore pregnant women and 2.54 crore newborns each year through a cold chain network spanning nearly 30,000 points and using more than 1.06 lakh ice-lined refrigerators and deep freezers. Full immunization coverage reached 98.4% by January 2026, demonstrating that temperature-controlled distribution has extended beyond the main urban corridors into harder-to-serve districts. India also launched a nationwide HPV vaccination campaign on February 28, 2026, adding a new layer of planned volume to the public cold chain at a time when service levels are already under pressure. The expansion of eVIN and U-WIN improves stock visibility, session planning, and distribution control, which supports more predictable movement across the India healthcare cold chain logistics market and reduces avoidable temperature risk in public health delivery. This demand is also important for the private side of the India healthcare cold chain logistics market because vaccine-linked assets often support adjacent pharmaceutical loads when campaigns are not at peak intensity.

Biologics and Biosimilars Scale-Up

The move from small-molecule medicines toward biologics and biosimilars is changing how the India healthcare cold chain logistics market allocates capital, because these therapies need tighter control during storage, handling, and movement. Most biosimilars depend on controlled 2 °C to 8 °C conditions, which means temperature integrity becomes part of product quality rather than a distribution preference. This is pushing more business toward GDP-capable operators that can offer validated lanes, continuous monitoring, and audit-ready documentation, while smaller non-specialized operators face growing exclusion from complex healthcare contracts. It is also driving demand in Hyderabad, Bengaluru, Pune, and Ahmedabad, where healthcare logistics providers are building certified capacity near biopharma production and export nodes. As that shift continues, the India healthcare cold chain logistics market is separating into a higher-value compliance tier and a lower-value conventional tier, with pricing power increasingly concentrated in the first group.

GDP-Grade Capex and Energy Cost Burden

GDP-grade pharmaceutical cold infrastructure requires validated mapping, redundant power, continuous logging, documented deviation handling, and system discipline that many smaller operators still struggle to fund. The burden is more severe because only 8% to 10% of India's 3,500-plus cold chain operators currently meet GDP compliance benchmarks, which shows how uneven the base has remained even as customer requirements tighten. This raises barriers to entry in the India healthcare cold chain logistics market and shifts share toward larger operators that can finance equipment, monitoring systems, and process control at scale. It also limits expansion into smaller cities, because the revenue available in many Tier-2 and Tier-3 locations does not always justify high-cost compliant assets during the early years. The near-term effect is better average quality in major corridors, but the tradeoff is slower geographic spread for the India healthcare cold chain logistics market outside the strongest pharmaceutical and hospital clusters.

Other drivers and restraints analyzed in the detailed report include:

1. Pharma Export Cold-Chain Compliance Demand
2. Specialty Injectables and Clinical-Trial Flow Growth
3. Rural Last-Mile and Multimodal Cold Gaps

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Transportation held 52.47% of the India healthcare cold chain logistics market share in 2025, which kept it as the largest functional block. Road transport remains the core of that segment because pharmaceutical shipments still require flexible point-to-point delivery across hospitals, distributors, plants, and regional stock points. The strength of road movement reflects India's geographic spread and the need to reach smaller consumption centers that air and rail cannot directly serve. Reefer trucks equipped with GPS tracking and data loggers remain central to this operating model because they support both route visibility and documented temperature control during transit. This means transport scale still sets the volume base for the India healthcare cold chain logistics market, even as customers become more selective about service quality. Maersk's dedicated reefer rail service from Hyderabad to Mumbai showed that temperature-controlled pharmaceutical movement can be integrated into multimodal planning when schedules and container standards are reliable. Transportation, therefore, continues to anchor the India healthcare cold chain logistics industry, while modal diversification slowly improves network depth.

Value-added services are the fastest-growing function, expanding at a 6.74% CAGR through 2031, which shows how the service mix is shifting beyond pure movement or storage. Customers increasingly want track-and-trace, digital temperature certificates, risk alerts, repackaging under controlled conditions, and support during deviations, because those features simplify audits and reduce the burden on internal quality teams. Kuehne+Nagel's HealthChain-certified setup in Bengaluru and Hyderabad reflects this direction, as the company has tied controlled storage and cross-dock capability into a broader healthcare service package. This is improving margin potential for operators that can bundle multiple services around sensitive product flows rather than compete only on line-haul price. In practice, value-added services are becoming one of the clearest differentiators inside the India healthcare cold chain logistics market.

Chilled storage at 2 °C to 8 °C accounted for 46.11% of the India healthcare cold chain logistics market share in 2025, which made it the leading temperature band. That leadership reflects the daily operating base of vaccines, insulin, and many conventional biologics, all of which move through this range on a recurring basis. The chilled band also benefits from a wider installed base across warehouses, hospitals, and distribution points, which makes it the most practical temperature class for broad healthcare coverage. Because so many essential therapies sit within this temperature requirement, chilled handling remains the revenue foundation of the India healthcare cold chain logistics market. It also shapes how new operators prioritize their initial infrastructure and route design.

Frozen storage from minus 18 °C to 0 °C is projected to grow at a 9.91% CAGR through 2031, which makes it the fastest-moving temperature type. This growth points to a deeper change in pharmaceutical mix, where biosimilar injectables, monoclonal antibodies, and plasma-derived products are taking a larger role in value terms. The frozen segment, therefore, represents a more specialized layer of the India healthcare cold chain logistics market, one that demands stronger process discipline and more selective customer qualification. As frozen products grow, operators will need better insulation, tighter loading practices, and more capable alarm-response systems across both storage and movement. The result is a temperature mix that is steadily shifting toward higher operational intensity across the India healthcare cold chain logistics market.

Complete Report Scope:

• By Logistics Function
  • Transportation
    • Road
    • Air
    • Sea and Inland Waterways
    • Rail
  • Warehousing and Distribution
  • Value-added Services and Others
• By Temperature Type
  • Chilled (0-5 °C)
  • Frozen (-18-0 °C)
  • Ambient
  • Deep-Frozen / Ultra-Low (less than-20 °C)
• By Product Type
  • Pharmaceuticals
    • Prescription and Speciality Drugs
    • OTC Drugs
  • Biopharmaceuticals (Biologics and Biosimilars)
  • Vaccines
  • Clinical Trail Materials
  • Cell and Gene Therapies
  • Medical Devices
  • Veterinary Medicine
  • Blood, Plasma and Blood Components
  • Diagnostic and Laboratory Products
  • Organs and Human Tissues
  • Others
• By Destination
  • Domestics
  • International
• By End User
  • Pharmaceutical Manufacturers
  • Biopharmaceutical Manufacturers
  • Hospitals and Clinics
  • Hospitals and Retail Pharmacies
  • Healthcare Distributors and Wholesalers
  • Others
• By Region
  • North
  • Central
  • West
  • East
  • South

List of Companies Covered in this Report:

1. DHL Group
2. United Parcel Service of America, Inc. (UPS)
3. Kuehne+Nagel
4. Snowman Logistics
5. Safexpress Pvt. Ltd.
6. DSV A/S (Including DB Schenker)
7. FedEx
8. Celcius Logistics
9. Indicold
10. Allcargo Gati Logistics Pvt. Ltd.
11. Mahindra Logistics, Ltd.
12. Transport Corporation of India, Ltd.
13. Container Corporation of India, Ltd.
14. Coldman Logistics
15. Parazelsus India
16. Glacias Supply Chain
17. World Courier
18. Biocair India
19. NYK Line (Including Yusen Logistics)
20. Jeena Criticare Logistics
21. Airfield Express
22. Harisons Logistics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview and Role of Cold Chain Logistics in Healthcare
• 4.2 Healthcare Spending Trends
• 4.3 Market Drivers
  • 4.3.1 Vaccine and Immunization Throughput Expansion
  • 4.3.2 Biologics and Biosimilars Scale-Up
  • 4.3.3 Pharma Export Cold-Chain Compliance Demand
  • 4.3.4 Specialty Injectables and Clinical-Trial Flow Growth
  • 4.3.5 Evin and U-WIN Demand-Visibility Gains
  • 4.3.6 Emerging Cell and Gene Therapy Lanes
• 4.4 Market Restraints
  • 4.4.1 GDP-Grade Capex and Energy Cost Burden
  • 4.4.2 Rural Last-Mile and Multimodal Cold Gaps
  • 4.4.3 GDP-Trained Talent and SOP Shortages
  • 4.4.4 Heat Stress and Backup-Power Vulnerability
• 4.5 Regulatory Framework
• 4.6 Value Chain and Distribution Channel Architecture Analysis
• 4.7 Technology Innovations Outlook
• 4.8 Porter's Five Forces Analysis
  • 4.8.1 Threat of New Entrants
  • 4.8.2 Bargaining Power of Suppliers
  • 4.8.3 Bargaining Power of Buyers
  • 4.8.4 Threat of Substitutes
  • 4.8.5 Rivalry Among Competitors
• 4.9 Evolution of Healthcare Cold Chain Logistics Requirements
• 4.10 Impact of Geo-Political Events on Supply Chain Shifts

5 Market Size and Growth Forecasts

• 5.1 By Logistics Function
  • 5.1.1 Transportation
    • 5.1.1.1 Road
    • 5.1.1.2 Air
    • 5.1.1.3 Sea and Inland Waterways
    • 5.1.1.4 Rail
  • 5.1.2 Warehousing and Distribution
  • 5.1.3 Value-added Services and Others
• 5.2 By Temperature Type
  • 5.2.1 Chilled (0-5 °C)
  • 5.2.2 Frozen (-18-0 °C)
  • 5.2.3 Ambient
  • 5.2.4 Deep-Frozen / Ultra-Low (less than-20 °C)
• 5.3 By Product Type
  • 5.3.1 Pharmaceuticals
    • 5.3.1.1 Prescription and Speciality Drugs
    • 5.3.1.2 OTC Drugs
  • 5.3.2 Biopharmaceuticals (Biologics and Biosimilars)
  • 5.3.3 Vaccines
  • 5.3.4 Clinical Trail Materials
  • 5.3.5 Cell and Gene Therapies
  • 5.3.6 Medical Devices
  • 5.3.7 Veterinary Medicine
  • 5.3.8 Blood, Plasma and Blood Components
  • 5.3.9 Diagnostic and Laboratory Products
  • 5.3.10 Organs and Human Tissues
  • 5.3.11 Others
• 5.4 By Destination
  • 5.4.1 Domestics
  • 5.4.2 International
• 5.5 By End User
  • 5.5.1 Pharmaceutical Manufacturers
  • 5.5.2 Biopharmaceutical Manufacturers
  • 5.5.3 Hospitals and Clinics
  • 5.5.4 Hospitals and Retail Pharmacies
  • 5.5.5 Healthcare Distributors and Wholesalers
  • 5.5.6 Others
• 5.6 By Region
  • 5.6.1 North
  • 5.6.2 Central
  • 5.6.3 West
  • 5.6.4 East
  • 5.6.5 South

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Key Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (Includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products and Services, and Recent Developments)
  • 6.4.1 DHL Group
  • 6.4.2 United Parcel Service of America, Inc. (UPS)
  • 6.4.3 Kuehne+Nagel
  • 6.4.4 Snowman Logistics
  • 6.4.5 Safexpress Pvt. Ltd.
  • 6.4.6 DSV A/S (Including DB Schenker)
  • 6.4.7 FedEx
  • 6.4.8 Celcius Logistics
  • 6.4.9 Indicold
  • 6.4.10 Allcargo Gati Logistics Pvt. Ltd.
  • 6.4.11 Mahindra Logistics, Ltd.
  • 6.4.12 Transport Corporation of India, Ltd.
  • 6.4.13 Container Corporation of India, Ltd.
  • 6.4.14 Coldman Logistics
  • 6.4.15 Parazelsus India
  • 6.4.16 Glacias Supply Chain
  • 6.4.17 World Courier
  • 6.4.18 Biocair India
  • 6.4.19 NYK Line (Including Yusen Logistics)
  • 6.4.20 Jeena Criticare Logistics
  • 6.4.21 Airfield Express
  • 6.4.22 Harisons Logistics

7 Market Opportunities and Future Outlook

• 7.1 White-space and Unmet-Need Assessment